Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.616,68
0,20%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Revelation Biosciences Inc (REVBW) Revelation Biosciences Inc (REVBW) Notizie

REVBW

Revelation Biosciences (REVBW)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:REVBW
DataOraFonteTitoloSimboloCompagnia
16/05/202422:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBWRevelation Biosciences Inc
10/05/202422:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:REVBWRevelation Biosciences Inc
15/08/202223:30GlobeNewswire Inc.Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate ProgressNASDAQ:REVBWRevelation Biosciences Inc
29/07/202217:45GlobeNewswire Inc.Revelation Biosciences Inc. Announces Closing of $5 Million Public OfferingNASDAQ:REVBWRevelation Biosciences Inc
26/07/202214:15GlobeNewswire Inc.Revelation Biosciences Inc. Announces Pricing of $5 Million Public OfferingNASDAQ:REVBWRevelation Biosciences Inc
23/07/202200:30GlobeNewswire Inc.Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic RhinitisNASDAQ:REVBWRevelation Biosciences Inc
14/07/202215:00GlobeNewswire Inc.Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic RhinitisNASDAQ:REVBWRevelation Biosciences Inc
13/06/202215:00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis NASDAQ:REVBWRevelation Biosciences Inc
23/05/202215:00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic RhinitisNASDAQ:REVBWRevelation Biosciences Inc
16/05/202222:01GlobeNewswire Inc.Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate ProgressNASDAQ:REVBWRevelation Biosciences Inc
06/04/202215:00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate UpdateNASDAQ:REVBWRevelation Biosciences Inc
30/03/202215:00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza InfectionNASDAQ:REVBWRevelation Biosciences Inc
24/03/202214:00GlobeNewswire Inc.Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza InfectionNASDAQ:REVBWRevelation Biosciences Inc
22/03/202214:00GlobeNewswire Inc.Revelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLCNASDAQ:REVBWRevelation Biosciences Inc
15/03/202214:00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99 for the Prevention of H3N2 Influenza InfectionNASDAQ:REVBWRevelation Biosciences Inc
08/03/202215:00GlobeNewswire Inc.Revelation Biosciences Inc. to Present at the 34th Annual Roth ConferenceNASDAQ:REVBWRevelation Biosciences Inc
07/02/202215:00GlobeNewswire Inc.Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor ConferenceNASDAQ:REVBWRevelation Biosciences Inc
24/01/202214:00GlobeNewswire Inc.Revelation Biosciences Raises $7.76 Million in Equity FinancingNASDAQ:REVBWRevelation Biosciences Inc
20/01/202215:00GlobeNewswire Inc.Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza InfectionNASDAQ:REVBWRevelation Biosciences Inc
18/01/202215:00GlobeNewswire Inc.Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic RhinitisNASDAQ:REVBWRevelation Biosciences Inc
13/01/202219:54GlobeNewswire Inc.REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public CompanyNASDAQ:REVBWRevelation Biosciences Inc
11/01/202215:00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public CompanyNASDAQ:REVBWRevelation Biosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:REVBW

La tua Cronologia

COIN
FXLUST
FXL
BIT
UC1C3C
Unicredit Bank
POLO
DCRUSDT
Decred
BIT
UC78NS
Unicredit Bank
BIT
UC8C6Z
Unicredit Bank
COIN
DATXUSD
DATx
TG
PNL
Essential Metals
EU
XS2808184969
ING Bank Bond 3.115% 22a...
BMF
SEKU24
SEKU24 - Setembro 2024
XE
BST
Bastei Luebbe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network